Evidence map›Paper›PMID 38521844›Full record

ReviewCell death and differentiation2024

Diverse functions of cytochrome c in cell death and disease.

Zhuan Zhou, Tasnim Arroum, Xu Luo, Rui Kang, Yong J Lee, Daolin Tang, Maik Hüttemann, Xinxin Song

Open access · greenAbstract readReview
In one paragraph

Review in Cell death and differentiation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
29.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 128 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Zhuan ZhouDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Tasnim ArroumCenter for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, 48201, USA.ORCID 0009-0004-9644-3494
Xu LuoEppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Rui KangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID 0000-0003-2725-1574
Yong J LeeDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Daolin TangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA. daolin.tang@utsouthwestern.edu.ORCID 0000-0002-1903-6180
Maik HüttemannCenter for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, 48201, USA. mhuttema@med.wayne.edu.ORCID 0000-0001-6310-7081
Xinxin SongDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA. xinxin.song@utsouthwestern.edu.ORCID 0000-0003-3868-2644
Southwestern Medical Center · USWayne State University · USCedars-Sinai Medical Center · USUniversity of Nebraska Medical Center · US

Funding

Development and Testing of LUCID: A Therapeutic Device for Brain Injury Following Infant Cardiac ArrestU44NS125160 · NINDS · MITOVATION, INC. · PI MAIK HUETTEMANN, Thomas Hudson Sanderson · 2022 to 2026
$3.6M
Targeting HMGB1-mediated Autophagy in Cancer TherapyR01CA160417 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2012 to 2023
$3.0M
Non-invasive mitochondrial modulation therapy for ischemic strokeR01NS120322 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUETTEMANN, MAIK, SANDERSON, THOMAS HUDSON · 2021 to 2025
$2.3M
Mechanisms of Ferroptotic Cancer Cell DeathR01CA229275 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2019 to 2024
$1.8M
Assessment of hyperthermia-based multimodal approach for hepatic colorectal metastasesR01CA265827 · NCI · CEDARS-SINAI MEDICAL CENTER · PI YONG JUN LEE · 2023 to 2026
$1.8M
The Pancreatic Cancer MicroenvironmentR01CA211070 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KANG, RUI · 2017 to 2023
$1.4M
Application of in vivo humanized PDX mouse model and ex vivo organoid model to assess the therapeutic efficacy of combinatorial therapy for pseudomyxoma peritoneiR21CA259243 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, YONG J · 2022 to 2023
$412k
NCI NIH HHS R01 CA160417NCI NIH HHS R01 CA211070NCI NIH HHS R01 CA229275NCI NIH HHS R01 CA265827NCI NIH HHS R21 CA259243NINDS NIH HHS R01 NS120322NINDS NIH HHS U44 NS125160
6 · The paper itself

Abstract

The redox-active protein cytochrome c is a highly positively charged hemoglobin that regulates cell fate decisions of life and death. Under normal physiological conditions, cytochrome c is localized in the mitochondrial intermembrane space, and its distribution can extend to the cytosol, nucleus, and extracellular space under specific pathological or stress-induced conditions. In the mitochondria, cytochrome c acts as an electron carrier in the electron transport chain, facilitating adenosine triphosphate synthesis, regulating cardiolipin peroxidation, and influencing reactive oxygen species dynamics. Upon cellular stress, it can be released into the cytosol, where it interacts with apoptotic peptidase activator 1 (APAF1) to form the apoptosome, initiating caspase-dependent apoptotic cell death. Additionally, following exposure to pro-apoptotic compounds, cytochrome c contributes to the survival of drug-tolerant persister cells. When translocated to the nucleus, it can induce chromatin condensation and disrupt nucleosome assembly. Upon its release into the extracellular space, cytochrome c may act as an immune mediator during cell death processes, highlighting its multifaceted role in cellular biology. In this review, we explore the diverse structural and functional aspects of cytochrome c in physiological and pathological responses. We summarize how posttranslational modifications of cytochrome c (e.g., phosphorylation, acetylation, tyrosine nitration, and oxidation), binding proteins (e.g., HIGD1A, CHCHD2, ITPR1, and nucleophosmin), and mutations (e.g., G41S, Y48H, and A51V) affect its function. Furthermore, we provide an overview of the latest advanced technologies utilized for detecting cytochrome c, along with potential therapeutic approaches related to this protein. These strategies hold tremendous promise in personalized health care, presenting opportunities for targeted interventions in a wide range of conditions, including neurodegenerative disorders, cardiovascular diseases, and cancer.

Indexed as

Cytochromes cAnimalsApoptosisCell DeathHumansMitochondriaNeoplasmsNucleophosminProtein Processing, Post-TranslationalCytochromes cNucleophosmin

Identifiers

PMID38521844
PMCPMC11043370
OpenAlexW4393119333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.